BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by Oppenheimer
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a report issued on Monday, Marketbeat Ratings reports. Oppenheimer currently has $98.00 price target on the biotechnology company’s stock. BMRN has been the subject of a number of other reports. Bank of America lifted their […]
27 Feb 07:10 · The Markets Daily